Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment. | J Transl Med | 2023 | 37085802 | PubTator, text mining | PubMed |
| Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays. | BMC Cancer | 2023 | 37085799 | PubTator, text mining | PubMed |
| The association between age at breast cancer diagnosis and prevalence of pathogenic variants. | Breast Cancer Res Treat | 2023 | 37084156 | PubTator, text mining | PubMed |
| Ubiquitin E3 ligases in cancer: somatic mutation and amplification. | BMB Rep | 2023 | 37081755 | PubTator, text mining | PubMed |
| Next-generation sequencing study on poorly differentiated carcinoma derived from a thirty-year-old epidermoid cyst: A case report. | Front Oncol | 2023 | 37077824 | PubTator, text mining | PubMed |
| Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification. | J Proteome Res | 2023 | 37071664 | PubTator, text mining | PubMed |
| Health Disparities in Presentation, Treatment, Genomic Testing, and Outcomes of Pancreatic Cancer in Hispanic and Non-Hispanic Patients. | J Racial Ethn Health Disparities | 2023 | 37071331 | PubTator, text mining | PubMed |
| New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers. | Cancer Drug Resist | 2023 | 37065862 | PubTator, text mining | PubMed |
| Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis. | Front Genet | 2023 | 37065479 | PubTator, text mining | PubMed |
| Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients. | Front Oncol | 2023 | 37064136 | PubTator, text mining | PubMed |
| Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. | Genome Med | 2023 | 37060015 | PubTator, text mining | PubMed |
| TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer. | Cancer Res | 2023 | 37057595 | PubTator, text mining | PubMed |
Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling. | BMC Cancer | 2023 | 37055759 | PubTator, text mining | PubMed |
| Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab. | Front Immunol | 2023 | 37051241 | PubTator, text mining | PubMed |
| Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment. | ACS Omega | 2023 | 37033796 | PubTator, text mining | PubMed |
| Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. | J Gastroenterol | 2023 | 37029223 | PubTator, text mining | PubMed |
| Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. | Nat Commun | 2023 | 37029129 | PubTator, text mining | PubMed |
| A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report. | Front Oncol | 2023 | 37025588 | PubTator, text mining | PubMed |
| Mitochondria-associated gene expression perturbation predicts clinical outcomes and shows potential for targeted therapy in neuroblastoma. | Front Pediatr | 2023 | 37025299 | PubTator, text mining | PubMed |
| Germline (epi)genetics reveals high predisposition in females: a 5-year, nationwide, prospective Wilms tumour cohort. | J Med Genet | 2023 | 37019617 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=30